Tempus AI's financials have significantly improved, with positive cash flow expected next quarter. Read why TEM stock is a ...

Amid increasing economic tensions with the United States, China recently announced that it would ban Illumina, a U.S.-based company and the ...

In a report released yesterday, Conor McNamara from RBC Capital maintained a Buy rating on Illumina (ILMN – Research Report), with a price ...

Goldman Sachs upgrades GE Healthcare to Buy, raising its price target to $100, as analysts see market stabilization and China sales recovering faster than expected.

Illumina will seek to cut $100 million in expenses by the end of this fiscal year as it plans to deal with a loss of revenue ...

Shares of Illumina Inc. ILMN rose 2.33% to $86.62 Friday, on what proved to be an all-around positive trading session for the ...

What a brutal six months it’s been for Illumina. The stock has dropped 30.9% and now trades at $84.65, rattling many shareholders. This may have investors wondering how to approach the situation.

China imposed an import ban on Illumina’s gene sequencers in response to President Trump’s escalating tariffs and trade war ...

Illumina navigates competition and geopolitical risks with improved margins and strong cash flow. Read my analysis of ILMN stock.

Illumina faces a new challenge as China has prohibited the import of the company’s sequencers ... Meanwhile, Citi analysts foresee continued pressure on the stock, highlighting competition from ...